Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval

Keytruda Qlex, an injectable version of Merck’s cancer immunotherapy, can be administered in minutes compared to the 30 minutes needed to dose the original infused formulation. The FDA approval is based on clinical trial results showing the injectable formulation was comparable to infused Keytruda. The post Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins…

Read More

Inequality aversion and option value

Many policymakers aim to reduce health disparities across groups. In fact, the distributional cost effectiveness analysis (DCEA) approach aims to incorporate treatment value based on the extent to which they reduce inequality. However, what types of inequality are we trying to reduce: ex-post or ex-ante? Ex post inequality means reducing inequality of outcomes at a…

Read More

Scaling Virtual Care Is Both a Moral and Financial Imperative, Sanford Health Exec Says

At MedCity News’ INVEST Digital Health conference, Sanford Health’s virtual care chief Dave Newman pointed out that in rural America, virtual care often determines whether patients receive treatment at all. He described how Sanford has expanded beyond video visits to include various other modalities like e-visit questionnaires, remote monitoring and even phone consults — saving…

Read More

Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease

Dualitas Therapeutics designs bispecific antibodies to hit to two targets on the same immune cell, leveraging proximity biology to provide benefit beyond what’s possible with monoclonal antibody drugs. Eli Lilly and Chugai Pharmaceutical are among the investors in the immunology and inflammation startup. The post Two Is Better Than One: Startup Dualitas Lands $65M to…

Read More